Page last updated: 2024-11-12
monacolin j
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
monacolin J: isolated from Monascus ruber; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
monacolin J : A polyketide that is monacolin L bearing an additional hydroxy substituent at position 8. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9905162 |
| CHEBI ID | 79034 |
| SCHEMBL ID | 1820283 |
| MeSH ID | M0131965 |
Synonyms (21)
| Synonym |
|---|
| p5iq0si56n , |
| unii-p5iq0si56n |
| 79952-42-4 |
| monacolin j |
| 2h-pyran-2-one, 6-(2-(1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthalenyl)ethyl)tetrahydro-4-hydroxy- |
| antibiotic mb 530a |
| 6(r)-[2-(8(s)-hydroxy]-2(s),6(r)-dimethyl-1,2,6,7,8,8a(r)-hexahydro-1(s)-naphthyl]ethyl-4(r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-one |
| lovastatin diol lactone |
| 2h-pyran-2-one, 6-(2-((1s,2s,6r,8s,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthalenyl)ethyl)tetrahydro-4-hydroxy-, (4r,6r)- |
| AKOS022183350 |
| monacolin j lactone |
| CHEBI:79034 |
| (4r,6r)-4-hydroxy-6-{2-[(1s,2s,6r,8s,8ar)-8-hydroxy-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]ethyl}tetrahydro-2h-pyran-2-one |
| SCHEMBL1820283 |
| monakolin j |
| CS-0027590 |
| HY-104051 |
| Q15720548 |
| ES-2535 |
| lovastatin diol lactone ((4r,6r)-6-[2-[(1s,2s,6r,8s,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthalenyl]ethyl]tetrahydro-4-hydroxy-2h-pyran-2-one) |
| DTXSID801031414 |
Research Excerpts
Overview
Monacolin J is a key precursor for the synthesis of simvastatin (Zocor), an important drug for treating hypercholesterolemia. It is also an intermediate of lovastatin biosynthesis.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Monacolin J is a key precursor for the synthesis of simvastatin (Zocor), an important drug for treating hypercholesterolemia. " | ( Single-step production of the simvastatin precursor monacolin J by engineering of an industrial strain of Aspergillus terreus. Huang, X; Liang, Y; Lu, X; Yang, Y, 2017) | 2.15 |
| "Monacolin J is a key intermediate during simvastatin synthesis, and also an intermediate of lovastatin biosynthesis." | ( [One-step fermentation for producing simvastatin via RNAi silencing of lovF gene in Aspergillus terreus]. Huang, J; Li, M; Li, N; Yu, Z; Zhou, J, 2016) | 1.16 |
| "Monacolin J is a key precursor for the synthesis of the cholesterol-lowering drug simvastatin. " | ( Construction of an Efficient and Robust Aspergillus terreus Cell Factory for Monacolin J Production. Huang, X; Lu, X; Tang, S; Teng, Y; Yang, Y; Zheng, L; Zhu, J, 2019) | 2.19 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (3)
| Role | Description |
|---|---|
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| fungal metabolite | Any eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds. |
| EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor | Any EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that inhibits HMG-CoA reductases. Hydroxymethylglutaryl-CoA reductase inhibitors have been shown to lower directly cholesterol synthesis. The Enzyme Commission designation is EC 1.1.1.34 for the NADPH-dependent enzyme and EC 1.1.1.88 for an NADH-dependent enzyme. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (5)
| Class | Description |
|---|---|
| secondary alcohol | A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it. |
| polyketide | Natural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides. |
| carbobicyclic compound | A bicyclic compound in which all the ring atoms are carbon. |
| 2-pyranones | A pyranone based on the structure of 2H-pyran-2-one and its substituted derivatives. |
| hexahydronaphthalenes | Any carbobycyclic compound that is an hexahydronaphthalene or a compound obtained from an hexahydronaphthalene by formal substitution of one or more hydrogens. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (21)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 10 (47.62) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 21.06
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.06) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (4.76%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 20 (95.24%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||